Power System Technology
ISSN:1000-3673

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

Bridging the Gap Between Bench and Bedside: A Comprehensive Review of Novel Biomaterials, Cellular Therapies, and Translational Modalities in Periodontal Regeneration

[1]Moteb Saeed Ali Alma, [2]Amjad Sultan Asiri, [3]May Ahmed Alfaleh, [4]Nasser Ahmed alfaleh, [5]Majed Althubaiti, [6]Nada Saad Alrashidi

[1]General Dentistry, Armed Forces Hospital, Southern Region, Khamis Mushait, SAU

[2]Dental assistant, Armed Forces Hospital, Southern Region, Khamis Mushait, SAU

[3]Dental general practitioner, East riyadh dental centre, Riyadh 2nd Cluster, Ministry of Health , Riyadh, SAU

[4]Restorative dentistry,Buraydah center hospital, alqassim cluster, ministry of health , Buraydah ,SAU

[5]Periodontics, Ministry of National Guard, Jeddah, SAU

[6]General Dentistry, Security Forces Hospital, Riyadh, SAU

Abstract

The regeneration of the periodontium aims to reconstruct the alveolar bone, periodontal ligament, and cementum destroyed by periodontitis, a widespread condition with global systemic risks. This article examines the fundamental biological drivers, including immune regulation, signaling cascades, and stem cell niches essential for repair. We also assess progress in material science, highlighting injectable hydrogels, nanofibrous grafts, and 3D-printed constructs alongside proven biologics such as platelet concentrates, enamel matrix proteins, and growth factors. Furthermore, emerging modalities like exosome therapy and smart scaffolds are evaluated. Despite persistent hurdles regarding regulation and individual patient variability, the integration of AI, minimally invasive techniques, and personalized care offers a promising path toward predictable periodontal restoration.

Keywords: Periodontal tissue engineering, Stem cells, Bioactive scaffolds, Platelet-rich fibrin (PRF), Enamel matrix derivative (EMD)

1. Introduction

Chronic periodontitis remains one of the most prevalent inflammatory disorders worldwide. Data covering the decade from 2011 to 2020 indicates that approximately 62% of dentate adults

Received: 08-06-2025 *Revised: 15-07-2025* *Accepted: 11-08-2025*

are affected, with nearly 23.6% suffering from severe manifestations of the disease [1]. This pathology is characterized by the irreversible destruction of the tooth-supporting apparatus, specifically the cementum, alveolar bone, and periodontal ligament (PDL). Without effective intervention, this deterioration invariably compromises function and esthetics, ultimately leading to tooth loss.

Over the last decade, scientific consensus has firmly established the link between oral inflammation and general systemic health. Periodontitis is now unequivocally associated with major systemic conditions, including diabetes mellitus, atherosclerotic cardiovascular disease, chronic kidney disease, rheumatoid arthritis, and adverse pregnancy outcomes [2,3]. These associations are driven by the systemic dissemination of pathogenic bacteria and inflammatory mediators, which synergistically amplify immune responses throughout the body [4].

Traditional periodontal therapies, ranging from non-surgical scaling and root planing to surgical interventions like flap debridement or osseous resection, are primarily designed to halt disease progression. While these modalities effectively reduce microbial burden and clinical inflammation, they rarely achieve the restoration of original periodontal architecture. Instead, the typical healing outcome is the formation of a long junctional epithelium rather than the regeneration of new bone, cementum, or functional PDL fibers [5].

True periodontal regeneration, in contrast, entails the complete biological and mechanical reconstitution of the lost attachment apparatus—bone, PDL, and cementum. Successful regeneration relies on the interplay of scaffold matrices, signaling molecules, and coordinated cellular activities to guide tissue formation [6]. Despite significant progress, achieving predictable and consistent outcomes remains a clinical challenge, particularly in complex defects such as furcation involvements and non-contained intrabony lesions.

The field has witnessed a paradigm shift in recent years due to breakthroughs in stem cell biology, biomaterial engineering, and translational medicine. Innovations such as 3D bio-printing, tissue-specific cell therapies, and controlled-release systems have revolutionized treatment possibilities. By integrating material science with biology, researchers are developing systems that not only provide structural support but also modulate immune responses to facilitate genuine tissue reconstruction. Consequently, this review aims to synthesize current progress in periodontal regeneration, focusing on biological principles, biomaterials, and emerging technologies supported by recent clinical evidence.

Here is the **Biological Basis** section, totally rewritten with elevated scientific vocabulary and smooth flow, ready for you to copy and paste.

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

2. Biological Basis of Periodontal Regeneration

Designing effective therapeutic strategies requires a profound comprehension of the periodontium's biological infrastructure. The periodontium is a complex organ composed of four distinct yet integrated tissues: the alveolar bone, root cementum, periodontal ligament (PDL), and gingiva. Each tissue possesses a unique cellular hierarchy, extracellular matrix (ECM) composition, and specific functional demands. Consequently, the destruction of these components during periodontal disease necessitates a multi-tissue regenerative approach that addresses the biological complexity of simultaneous soft and hard tissue reconstruction.

2.1 Periodontal Stem Cell Niches

Resident stem cell populations function as the cornerstone of regenerative therapy. Since their identification in 2004, Periodontal Ligament Stem Cells (PDLSCs) have become a focal point of research due to their clonogenicity, multipotency, and immunomodulatory capabilities [7]. Beyond PDLSCs, various other Mesenchymal Stem Cells (MSCs)—including those harvested from dental pulp (DPSCs), gingiva (GMSCs), alveolar periosteum, and bone marrow—have demonstrated significant potential in augmenting periodontal healing outcomes [7,8].

Current literature underscores that the therapeutic value of PDLSCs extends beyond their direct differentiation into osteoblasts and cementoblasts; they also secrete paracrine factors that regulate inflammation and drive angiogenesis [9]. Notably, exosomes derived from PDLSCs have been shown to influence macrophage plasticity, shifting them toward the M2 phenotype to support tissue remodeling and wound resolution [10]. However, the regenerative efficacy of these cells is heavily influenced by the local microenvironment. Chronic inflammation can severely compromise stem cell differentiation and ECM synthesis, suggesting that microenvironmental modulation is an essential adjuvant to cell-based therapies [11].

2.2 Signaling Pathways Governing Regeneration

The recruitment, proliferation, and lineage commitment of periodontal progenitor cells are governed by intricate signaling cascades. Key pathways include:

- **Bone Morphogenetic Proteins (BMPs):** specifically BMP-2 and BMP-7, are critical for inducing osteogenesis and cementogenesis [12].
- **Wnt/β-catenin Pathway:** acts as a central regulator of stem cell self-renewal and the differentiation of PDL fibroblasts [13].
- **Transforming Growth Factor-beta (TGF-β):** plays a vital role in ECM remodeling and angiogenesis, though its sustained overexpression carries a risk of fibrosis [14].

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

- **Platelet-Derived Growth Factor (PDGF):** serves as a potent mitogen that drives fibroblast proliferation, chemotaxis, and neovascularization [15].
- **Fibroblast Growth Factor-2 (FGF-2):** promotes the proliferation of MSCs and PDL cells while simultaneously supporting angiogenic processes [16].

Current research priorities focus on modulating these pathways—either via the direct delivery of recombinant growth factors or through gene therapy vectors—to enhance regenerative predictability.

2.3 Immune Modulation and Regeneration

Periodontal wound healing is fundamentally reliant on the modulation of the host immune response. The characteristics of the initial inflammatory phase dictate whether the outcome will be reparative scar tissue or true regeneration. Macrophages act as the "switch" in this process: the pro-inflammatory M1 phenotype drives defense mechanisms, whereas the anti-inflammatory M2 phenotype fosters tissue regeneration [17].

Emerging evidence suggests that immunomodulatory agents, including interleukin-4 (IL-4), exosomes, and specific synthetic peptides, can effectively steer macrophage polarization toward a regenerative state. A 2022 study by Wang et al. confirmed that defects treated with exosomes displayed significantly reduced inflammation and superior formation of new bone and cementum compared to controls [18]. Consequently, periodontal regeneration is no longer viewed solely as a structural challenge but as a complex immunobiological event requiring precise regulation of the host-response dynamics.

Here is Section 3, **Biomaterials in Periodontal Regeneration**, rewritten with sophisticated academic phrasing and formatted for immediate use.

3. Biomaterials in Periodontal Regeneration

Biomaterials serve as the structural backbone of regenerative therapy, providing the essential physicochemical framework required for neotissue development. Beyond simple scaffolding, modern biomaterials are engineered to actively facilitate cellular adhesion, migration, proliferation, and lineage differentiation. Furthermore, these constructs are increasingly designed to modulate local immune responses and function as delivery vehicles for therapeutic agents, thereby creating an optimized microenvironment for healing.

3.1 Bone Grafting Materials

Bone replacement grafts are utilized to reconstruct the lost alveolar volume and function as a matrix for osteogenesis. These materials are generally categorized into four distinct classes

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

based on their origin. **Autografts**, harvested directly from the patient (e.g., the mandibular symphysis), remain the gold standard due to their osteogenic potential, though their application is limited by donor site morbidity. **Allografts**, derived from human donors such as demineralized freeze-dried bone allograft (DFDBA), possess osteoinductive capabilities attributed to the preservation of bone morphogenetic proteins (BMPs) [19]. **Xenografts**, which involve the transplantation of tissue across species—most commonly bovine-derived—are extensively utilized in implant and periodontal surgery for their exceptional biocompatibility and capacity for space maintenance [20]. Finally, **Alloplasts** are synthetic substitutes like hydroxyapatite (HA), β-tricalcium phosphate (β-TCP), and bioactive glass; these are primarily osteoconductive and are frequently combined with biologics to augment their regenerative potential.

Contemporary research has pivoted toward the development of nanostructured alloplasts, which emulate the nanotopography of natural bone to enhance vascular infiltration and cell attachment. Notably, a split-mouth randomized controlled trial conducted in 2022 revealed that nanohydroxyapatite–collagen composites yielded clinical outcomes comparable to autografts in treating intrabony defects, while offering the advantages of reduced cost and lower morbidity [21].

3.2 Guided Tissue Regeneration (GTR) Membranes

The principle of Guided Tissue Regeneration (GTR) relies on the use of barrier membranes to mechanically exclude rapid epithelial downregulation, thereby privileging the defect site for repopulation by slower-growing periodontal ligament and bone cells. These barriers are broadly classified into **non-resorbable membranes**, such as expanded polytetrafluoroethylene (ePTFE), which necessitate a secondary retrieval surgery, and **resorbable membranes**, typically composed of collagen or polylactic acid, which undergo physiological degradation.

Recent technological strides have led to the creation of biofunctional membranes incorporated with antibiotics, growth factors (e.g., PDGF, BMP), or anti-inflammatory nanoparticles to actively promote healing. A clinical study from 2019 demonstrated that defects treated with BMP-2/BioCaP constructs in conjunction with barrier membranes exhibited significantly lower clinical attachment loss compared to controls [22]. Moreover, the engineering of functionally graded, multi-layered membranes designed to simultaneously orchestrate soft and hard tissue regeneration has shown superior efficacy in the management of complex furcation defects and combined endodontic-periodontal lesions.

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

3.3 Hydrogels and Injectable Systems

Hydrogels have emerged as a vanguard in scaffold technology, prized for their biocompatibility, minimally invasive injectability, and capacity to encapsulate bioactive payloads. Prominent formulations include gelatin methacryloyl (GelMA), which offers photocrosslinkable tunability; fibrin-based matrices often paired with platelet concentrates; and alginate or hyaluronic acid derivatives designed for pH-responsive degradation. A 2023 investigation utilizing PDLSC-loaded GelMA hydrogels enriched with BMP-2 reported superior vascularization and osteogenesis in murine periodontal defects compared to controls [23]. Furthermore, these platforms facilitate the spatiotemporal control of drug release, thereby mimicking the physiological cascade of natural wound healing.

3.4 3D-Printed and Biofabricated Scaffolds

Additive manufacturing, or 3D printing, enables the precise fabrication of patient-specific scaffolds that match unique defect topographies while optimizing porosity, degradation rates, and mechanical stiffness. Synthetic polymers such as polycaprolactone (PCL) and poly(lactic-co-glycolic acid) (PLGA), alongside bioceramics like β-tricalcium phosphate (β-TCP), are frequently utilized. To augment their regenerative potential, these constructs are increasingly bio-functionalized via surface coating with biologics or direct seeding with stem cells [24].

4. Biologics and Growth Factors in Periodontal Regeneration

Biologics constitute a category of bioactive agents engineered to orchestrate cellular behavior, stimulate angiogenesis, and drive lineage differentiation during tissue repair. In regenerative periodontology, these molecules are deployed either as monotherapies or as synergistic components within scaffold systems to optimize the local healing microenvironment.

4.1 Enamel Matrix Derivatives (EMDs)

Enamel Matrix Derivatives (EMDs) represent a cornerstone of regenerative therapy. Composed primarily of amelogenin extracted from porcine fetal tooth buds, EMDs biomimic the embryonic environment to induce cementoblast differentiation, periodontal ligament reattachment, and osteogenesis [25]. Contemporary meta-analyses substantiate EMD’s efficacy in improving clinical attachment levels (CAL) and reducing probing pocket depths (PPD), specifically within 2- and 3-wall intrabony defects [26]. Furthermore, a 2022 systematic review highlighted the positive impact of EMD as an adjunct to surgical and non-surgical debridement in managing peri-implant diseases [27]. Current protocols often combine EMD with collagen matrices or bone grafts; notably, EMD-impregnated collagen sponges used in

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

minimally invasive surgery have demonstrated accelerated wound healing and attenuated postoperative inflammation [12].

4.2 Platelet Concentrates: PRP, PRF, and CGF

Autologous platelet concentrates—including Platelet-Rich Plasma (PRP), Platelet-Rich Fibrin (PRF), and Concentrated Growth Factors (CGF)—serve as reservoirs for critical cytokines such as PDGF, TGF-β, VEGF, and IGF-1. Being autologous, they eliminate risks of immune rejection. Between 2019 and 2024, research has heavily favored advanced PRF variants (A-PRF+), which boast enriched leukocyte and cytokine profiles to boost vascularization. A 2023 randomized controlled trial quantified this benefit, reporting that the test group achieved a radiographic defect depth reduction of 1.57 mm versus 0.31 mm in controls, with significant intergroup differences ($P < .001$) [28].

PRF is also utilized to bio-activate inert scaffolds; when combined with β-TCP or hydroxyapatite, it accelerates bone maturation and vascular ingrowth [29]. Moreover, PRF membranes have shown utility across various procedures, including alveolar ridge preservation, sinus augmentation, and guided tissue regeneration (GTR) [30]. A notable innovation is Injectable PRF (i-PRF), a liquid-phase concentrate that polymerizes post-injection, showing promise in the minimally invasive management of both vertical and horizontal defects [31].

4.3 Recombinant Human Growth Factors

Recombinant growth factors are engineered to replicate endogenous signaling molecules essential for tissue morphogenesis.

4.3.1 PDGF-BB Platelet-Derived Growth Factor-BB (PDGF-BB), the first FDA-approved growth factor for periodontal use, exerts potent mitogenic and chemotactic effects on osteoblasts, periodontal ligament cells, and fibroblasts. Multicenter trials have consistently demonstrated that PDGF-BB delivered via β-TCP matrices yields superior defect fill and CAL gain compared to open flap debridement alone [32].

4.3.2 Bone Morphogenetic Proteins (BMPs) Bone Morphogenetic Proteins (BMPs), particularly BMP-2 and BMP-7, possess robust osteoinductive properties widely utilized in orthopedics. However, their periodontal application requires caution due to risks of ankylosis and root resorption if containment is compromised. Recent preclinical advances focus on controlled delivery systems, such as microspheres or hydrogels, to ensure localized release. A 2017 canine study evidenced that BMP-2 hydrogels significantly enhanced bone regeneration compared to grafting alone, without inducing adverse effects [33].

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

Here are Sections 5 and 6, totally rewritten to maintain a high-impact academic tone while preserving all your specific data points and references.

5. Cellular Therapies and Stem Cell–Based Approaches

Cellular therapeutics constitute the vanguard of regenerative periodontology. By harnessing the potency of mesenchymal stem/stromal cells (MSCs), these interventions aim to transcend simple structural repair, orchestrating a complex healing cascade via immunomodulation and the secretion of trophic factors.

5.1 Mesenchymal Stem Cells (MSCs)

MSCs isolated from diverse oral sources—including the periodontal ligament, dental pulp, apical papilla, and alveolar bone marrow—possess the intrinsic capacity for multi-lineage differentiation into cementoblast-like and osteoblast-like cells. Among these, Periodontal Ligament Stem Cells (PDLSCs) have garnered the most significant research interest due to their accessibility, low donor morbidity, and tissue-specific lineage commitment [34].

Recent clinical investigations have validated the efficacy of autologous PDLSC transplantation. When delivered via collagen carriers or engineered sheets, these cells yield significantly superior Clinical Attachment Level (CAL) gains and radiographic bone fill compared to conventional treatments. A pivotal 2023 pilot study utilizing PDLSC sheets reported a mean CAL gain of 2.5 ± 2.6 mm six months post-transplantation. Notably, these regenerative gains were maintained over a mean follow-up of 55 ± 19 months without any serious adverse events, suggesting long-term safety and stability [35].

5.2 Cell Sheets and Scaffold-Free Engineering

Pioneered in Japan, Cell Sheet Engineering (CSE) allows for the harvesting of cultured cells as intact, multilayered sheets that retain their extracellular matrix (ECM) and critical cell-to-cell adhesion proteins. This preservation enhances graft engraftment and potentiates paracrine signaling post-implantation. In preclinical models, PDLSC sheets combined with fibrin membranes have demonstrated accelerated periodontal reattachment [36].

Clinical validation was provided by a 2021 trial involving ten patients, which showed that 2- and 3-wall defects treated with PDLSC sheets exhibited superior regeneration compared to flap surgery alone. However, widespread adoption is currently hindered by high costs and the necessity for GMP-compliant cell processing facilities [35]. Alternatively, scaffold-free tissue engineering enables PDLCs to self-assemble into organized cementum-PDL complexes. These constructs serve a dual purpose: as implantable grafts for tissue restoration and as sophisticated in vitro models for studying the biological mechanisms of tissue assembly [37].

Power System Technology
ISSN:1000-3673

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

5.3 Exosomes and Secretome Therapies

To mitigate the risks associated with live cell transplantation, research has pivoted toward cell-free therapies utilizing MSC-derived exosomes. These nanoscale vesicles, laden with mRNA, microRNA, and bioactive proteins, recapitulate the regenerative potency of their parent cells. Exosomes are powerful mediators of angiogenesis, immune regulation, and matrix remodeling.

A 2022 murine study demonstrated that gelatin scaffolds loaded with exosomes significantly enhanced the formation of new cementum and PDL compared to scaffolds alone [38]. With Phase I trials already underway for general bone regeneration, the translation of exosome therapy to periodontal applications is anticipated in the near future.

6. Advanced Technologies in Periodontal Regeneration

Beyond the realm of biologics, cutting-edge technological innovations are reshaping periodontal therapy, offering unprecedented precision, predictability, and biological functionality.

6.1 3D Printing and Biofabrication

Additive manufacturing has revolutionized scaffold design, enabling the fabrication of patient-specific constructs with customized geometries, porosity, and mechanical stiffness. Polymers such as polycaprolactone (PCL) and polylactic acid (PLA) are frequently combined with bioactive ceramics in layer-by-layer printing processes to create architectures capable of hosting cells, growth factors, or platelet concentrates [39].

A 2023 systematic review highlighted that advanced, multi-compartment scaffolds designed to guide fiber orientation or release specific ions significantly improve periodontal regeneration in animal models [40].

6.2 Smart and Responsive Scaffolds

The next evolution in biomaterials involves "smart" matrices integrated with biosensing capabilities. These stimuli-responsive scaffolds react to local environmental triggers—such as pH changes, enzymatic activity, or reactive oxygen species (ROS)—to modulate their physical properties or release therapeutic payloads on demand.

For instance, self-assembling peptide (SAP) hydrogels have been engineered to release Interleukin-10 (IL-10) in a sustained manner. In vivo studies confirm that these SAP/IL-10 hydrogels significantly attenuate pro-inflammatory M1 macrophage polarization while upregulating osteogenic factors [41]. Other strategies utilize matrix metalloproteinase (MMP)-cleavable linkers to release growth factors only during periods of high enzymatic activity,

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

preventing premature washout. While largely preclinical, these technologies promise precise spatiotemporal control over the healing process.

6.3 Nanotechnology in Regeneration

Nanotechnology augments scaffold utility by dramatically increasing surface area to facilitate cell adhesion and bioactivity. Electrospun nanofiber meshes, which mimic the scale and architecture of natural ECM, have been proven to support fibroblast alignment and neovascularization [42].

Furthermore, nanoparticles serve as efficient vehicles for the controlled delivery of PDGF, BMPs, or antibiotics directly into the periodontal pocket. A notable study demonstrated that chitosan nanohydrogels incorporated into bone grafts yielded superior bone regenerative potential compared to open flap debridement with conventional grafting alone [43].

6.4 Photobiomodulation and Laser Therapies

Photobiomodulation (PBM), formerly known as Low-Level Laser Therapy (LLLT), is recognized for its ability to stimulate mitochondrial activity, reduce inflammation, and accelerate collagen synthesis. Recent evidence advocates for its synergistic use with surgical interventions to enhance soft tissue healing and potentially augment bone regeneration.

A recent study confirmed the beneficial impact of LLLT on clinical attachment levels, suggesting that when combined with the Single Flap Approach (SFA), LLLT enhances early wound stability and results in superior clinical outcomes, characterized by increased CAL gain and reduced probing depths [44].

7. Clinical Evidence and Human Trials

The translation of regenerative protocols from the laboratory bench to the clinical chairside mandates rigorous validation through controlled human studies. Efficacy is typically quantified via reductions in probing depth (PD), gains in clinical attachment level (CAL), and radiographic bone fill, alongside an increasing emphasis on patient-reported outcome measures (PROMs). The period between 2018 and 2024 has witnessed a proliferation of randomized controlled trials (RCTs) and systematic reviews, significantly fortifying the evidence base for various regenerative modalities.

7.1 Enamel Matrix Derivative (EMD)

Enamel Matrix Derivative (EMD) stands as a cornerstone biologic for the management of intrabony defects. A landmark 2019 meta-analysis encompassing 79 RCTs quantified that EMD application yields a mean CAL gain of 1.27 mm and superior bone fill compared to open flap debridement (OFD) alone [45]. Contemporary investigations have increasingly focused on the synergistic potential of combining EMD with bone grafts. Evidence suggests that severe intrabony defects can be successfully managed via this combination, provided that long-term stability is supported by strict patient compliance with maintenance protocols [46].

7.2 Platelet Concentrates (PRF/i-PRF)

Between 2018 and 2022, a robust body of high-quality evidence established Platelet-Rich Fibrin (PRF) and its injectable variants (i-PRF) as potent surgical adjuncts. When utilized in conjunction with non-surgical periodontal therapy, i-PRF demonstrated statistically significant improvements across all clinical parameters—including CAL, bleeding on probing (BOP), and plaque index—compared to non-surgical therapy alone [47]. Furthermore, a 2022 systematic review concluded that PRF is highly effective for infrabony defects, particularly regarding CAL gain and bone fill at six-month follow-ups. The data indicates that combining PRF with grafting materials may accelerate the osteogenic trajectory in these defects [48].

7.3 Recombinant Growth Factors

PDGF-BB Recombinant human PDGF-BB, when delivered via a β-tricalcium phosphate (β-TCP) carrier, has consistently demonstrated superior clinical efficacy. In randomized controlled trials, the rhPDGF-BB/β-TCP combination yielded significantly greater probing depth reduction, attachment gain, and defect fill compared to β-TCP alone at both 6 and 9 months [49][50]. Long-term evaluations have further corroborated these findings, reporting stable clinical and radiographic benefits extending up to 36 months [51].

BMP-2 While human clinical data regarding BMP-2 in periodontal defects remains nascent, preclinical models utilizing controlled-release systems, such as hydrogels, have demonstrated effective bone regeneration while mitigating associated risks like ankylosis and ectopic mineralization.

7.4 Stem Cell Therapies

Autologous PDLSCs A 2016 randomized clinical trial evaluated the safety and efficacy of autologous PDLSC sheets combined with bovine bone mineral for intrabony defects. While the procedure was deemed safe, regenerative gains were not statistically superior to conventional Guided Tissue Regeneration (GTR) [52]. Similarly, a 2020 quasi-randomized pilot study using PDLSC-loaded xenogeneic scaffolds in 1- and 2-wall defects confirmed safety but reported only modest clinical improvements [53].

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

Allogeneic Stem Cells Peer-reviewed human trials for allogeneic sources remain pending. While preclinical data is promising, rigorous clinical validation is required to establish protocols.

8. Challenges and Limitations

Despite the trajectory of innovation in periodontal regeneration, substantial biological, technical, regulatory, and economic impediments persist, hindering the universal standardization and adoption of these advanced therapies.

8.1 Biological and Clinical Variability

Defect morphology remains a primary determinant of regenerative success. A 2024 risk assessment emphasizes that deep, narrow, three-wall intrabony defects provide the optimal environment due to architectural support, clot stability, and vascularization. Conversely, patient-specific variables—including smoking status, uncontrolled diabetes, and oral hygiene adherence—drastically influence healing capacity [54]. Furthermore, intrinsic inter-individual variability in immune responses and stem cell potency complicates outcome predictability, leaving personalized medicine largely in the experimental phase.

8.2 Technical and Procedural Complexity

Achieving Primary Flap Closure The surgical execution demands high precision. Achieving tension-free, passive primary closure is non-negotiable for graft stability. While techniques such as the simplified papilla preservation flap are routine, even minor wound dehiscences can compromise results [55].

Handling Bioactive Scaffolds The manipulation of delicate membranes (e.g., ePTFE, collagen) to maintain space without tearing or displacement is technically exacting. Advanced flap management is often requisite to accommodate these materials effectively [56].

Preventing Early Membrane Exposure Membrane exposure is particularly deleterious to regenerative outcomes. In GTR procedures, exposure has been shown to diminish bone gain by approximately 80% (reducing average gain from ~3 mm to ~0.6 mm) [56].

8.3 Regulatory and Ethical Considerations

The regulatory landscape varies significantly across jurisdictions. While the FDA has cleared specific biologics like PDGF-BB, the approval pathways for stem cell therapies and gene-edited products differ globally. The translation of allogeneic products is further complicated by stringent requirements for immunogenicity profiling, sterility assurance, and Good Manufacturing Practice (GMP) compliance [57]. Moreover, ethical debates regarding the

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

sourcing of embryonic or fetal tissues necessitate the development of harmonized international frameworks for ethical oversight.

8.4 Long-Term Data and Histologic Evidence

The majority of clinical data relies on short-term follow-ups (6 to 12 months) utilizing surrogate clinical and radiographic endpoints. Studies providing long-term data (≥5 years) are scarce, and true histological verification of regeneration in humans remains rare due to ethical constraints [58,59,60]. Without such evidence, differentiating between functional repair (long junctional epithelium) and true periodontal reconstitution remains challenging. However, animal models continue to validate that biomimetic strategies can indeed regenerate organized cementum-PDL-bone complexes, underscoring the need for continued translational research [61].

7. Clinical Evidence and Human Trials

The translation of regenerative protocols from the laboratory bench to the clinical chairside mandates rigorous validation through controlled human studies. Efficacy is typically quantified via reductions in probing depth (PD), gains in clinical attachment level (CAL), and radiographic bone fill, alongside an increasing emphasis on patient-reported outcome measures (PROMs). The period between 2018 and 2024 has witnessed a proliferation of randomized controlled trials (RCTs) and systematic reviews, significantly fortifying the evidence base for various regenerative modalities.

7.1 Enamel Matrix Derivative (EMD)

Enamel Matrix Derivative (EMD) stands as a cornerstone biologic for the management of intrabony defects. A landmark 2019 meta-analysis encompassing 79 RCTs quantified that EMD application yields a mean CAL gain of 1.27 mm and superior bone fill compared to open flap debridement (OFD) alone [45]. Contemporary investigations have increasingly focused on the synergistic potential of combining EMD with bone grafts. Evidence suggests that severe intrabony defects can be successfully managed via this combination, provided that long-term stability is supported by strict patient compliance with maintenance protocols [46].

7.2 Platelet Concentrates (PRF/i-PRF)

Between 2018 and 2022, a robust body of high-quality evidence established Platelet-Rich Fibrin (PRF) and its injectable variants (i-PRF) as potent surgical adjuncts. When utilized in conjunction with non-surgical periodontal therapy, i-PRF demonstrated statistically significant improvements across all clinical parameters—including CAL, bleeding on probing (BOP), and plaque index—compared to non-surgical therapy alone [47]. Furthermore, a 2022 systematic

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

review concluded that PRF is highly effective for infrabony defects, particularly regarding CAL gain and bone fill at six-month follow-ups. The data indicates that combining PRF with grafting materials may accelerate the osteogenic trajectory in these defects [48].

7.3 Recombinant Growth Factors

PDGF-BB Recombinant human PDGF-BB, when delivered via a β-tricalcium phosphate (β-TCP) carrier, has consistently demonstrated superior clinical efficacy. In randomized controlled trials, the rhPDGF-BB/β-TCP combination yielded significantly greater probing depth reduction, attachment gain, and defect fill compared to β-TCP alone at both 6 and 9 months [49][50]. Long-term evaluations have further corroborated these findings, reporting stable clinical and radiographic benefits extending up to 36 months [51].

BMP-2 While human clinical data regarding BMP-2 in periodontal defects remains nascent, preclinical models utilizing controlled-release systems, such as hydrogels, have demonstrated effective bone regeneration while mitigating associated risks like ankylosis and ectopic mineralization.

7.4 Stem Cell Therapies

Autologous PDLSCs A 2016 randomized clinical trial evaluated the safety and efficacy of autologous PDLSC sheets combined with bovine bone mineral for intrabony defects. While the procedure was deemed safe, regenerative gains were not statistically superior to conventional Guided Tissue Regeneration (GTR) [52]. Similarly, a 2020 quasi-randomized pilot study using PDLSC-loaded xenogeneic scaffolds in 1- and 2-wall defects confirmed safety but reported only modest clinical improvements [53].

Allogeneic Stem Cells Peer-reviewed human trials for allogeneic sources remain pending. While preclinical data is promising, rigorous clinical validation is required to establish protocols.

8. Challenges and Limitations

Despite the trajectory of innovation in periodontal regeneration, substantial biological, technical, regulatory, and economic impediments persist, hindering the universal standardization and adoption of these advanced therapies.

8.1 Biological and Clinical Variability

Defect morphology remains a primary determinant of regenerative success. A 2024 risk assessment emphasizes that deep, narrow, three-wall intrabony defects provide the optimal environment due to architectural support, clot stability, and vascularization. Conversely,

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

patient-specific variables—including smoking status, uncontrolled diabetes, and oral hygiene adherence—drastically influence healing capacity [54]. Furthermore, intrinsic inter-individual variability in immune responses and stem cell potency complicates outcome predictability, leaving personalized medicine largely in the experimental phase.

8.2 Technical and Procedural Complexity

Achieving Primary Flap Closure The surgical execution demands high precision. Achieving tension-free, passive primary closure is non-negotiable for graft stability. While techniques such as the simplified papilla preservation flap are routine, even minor wound dehiscences can compromise results [55].

Handling Bioactive Scaffolds The manipulation of delicate membranes (e.g., ePTFE, collagen) to maintain space without tearing or displacement is technically exacting. Advanced flap management is often requisite to accommodate these materials effectively [56].

Preventing Early Membrane Exposure Membrane exposure is particularly deleterious to regenerative outcomes. In GTR procedures, exposure has been shown to diminish bone gain by approximately 80% (reducing average gain from ~3 mm to ~0.6 mm) [56].

8.3 Regulatory and Ethical Considerations

The regulatory landscape varies significantly across jurisdictions. While the FDA has cleared specific biologics like PDGF-BB, the approval pathways for stem cell therapies and gene-edited products differ globally. The translation of allogeneic products is further complicated by stringent requirements for immunogenicity profiling, sterility assurance, and Good Manufacturing Practice (GMP) compliance [57]. Moreover, ethical debates regarding the sourcing of embryonic or fetal tissues necessitate the development of harmonized international frameworks for ethical oversight.

8.4 Long-Term Data and Histologic Evidence

The majority of clinical data relies on short-term follow-ups (6 to 12 months) utilizing surrogate clinical and radiographic endpoints. Studies providing long-term data (≥5 years) are scarce, and true histological verification of regeneration in humans remains rare due to ethical constraints [58,59,60]. Without such evidence, differentiating between functional repair (long junctional epithelium) and true periodontal reconstitution remains challenging. However, animal models continue to validate that biomimetic strategies can indeed regenerate organized cementum-PDL-bone complexes, underscoring the need for continued translational research [61].

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

9. Future Directions

The trajectory of periodontal regeneration is rapidly pivoting toward personalized, integrative, and ultra-minimally invasive paradigms. Several transformative avenues are currently under rigorous investigation.

9.1 Personalized Regeneration Using Biomarkers and AI

Current research paradigms are converging on precision medicine, utilizing proteomic analysis of gingival crevicular fluid and saliva—specifically targeting cytokines such as IL-1β, MMP-8, and TNF-α—to phenotype patients and customize therapeutic interventions. Concurrently, artificial intelligence is revolutionizing diagnostics; deep learning algorithms applied to Cone Beam Computed Tomography (CBCT) data are now capable of automated defect quantification and treatment planning [62, 63]. A 2023 investigation highlighted the robustness of these computational models, reporting a pooled sensitivity of 0.88, specificity of 0.82, and an Area Under the Curve (AUC) of ~0.92 for detecting alveolar bone loss [64].

9.2 Smart and Responsive Scaffolds

Material science is advancing the fabrication of "intelligent" matrices engineered to react to dynamic physiological cues. These bio-responsive scaffolds can sense microenvironmental shifts—such as pH fluctuations, enzymatic activity, or reactive oxygen species (ROS)—and trigger the on-demand release of therapeutic cargo. This capability allows for the real-time optimization of the regenerative cascade without external manipulation [65].

9.3 Cell-Free Therapies and Gene Editing

To circumvent the logistical and regulatory hurdles of live cell transplantation, attention is shifting toward cell-free secretome therapies. Exosomes, due to their low immunogenicity, "off-the-shelf" utility, and safety profile, represent a pragmatic alternative for future applications. In vitro assays confirm that PDLSC-derived exosomes effectively downregulate inflammatory cytokines in macrophages while simultaneously promoting osteogenesis [10].

Furthermore, genomic editing tools like CRISPR-Cas9 are being explored to potentiate stem cell efficacy, specifically by silencing pro-inflammatory pathways or upregulating osteogenic gene expression. While currently confined to preclinical murine models, these gene-edited PDLSCs have demonstrated superior regenerative capacity [66].

9.4 Minimally Invasive and Robotic-Assisted Delivery

The surgical landscape is evolving toward Minimally Invasive Surgical Techniques (MIST), including pinhole access flaps, designed to preserve vascular supply and soft tissue integrity

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

[67]. Emerging innovations include the integration of robotic microsurgery and endoscopic visualization to enhance precision in complex anatomical zones. Notably, a novel endoscopy-assisted Non-Incisional Regeneration Technique (NIT) has yielded statistically significant improvements in clinical and radiographic parameters, suggesting its viability as a non-surgical alternative for treating intrabony defects [68].

10. Conclusion

Periodontal regeneration has undergone a metamorphosis, evolving from foundational bone grafting and barrier techniques into a sophisticated discipline at the nexus of tissue engineering, molecular biology, and precision surgery. The interval between 2018 and 2024 has witnessed substantial breakthroughs in the engineering of bioactive scaffolds, stem cell delivery systems, and smart biomaterials capable of orchestrating intricate physiological responses.

Contemporary clinical trials continue to substantiate the efficacy of established biologics—including EMD, PRF, PDGF, and controlled-release BMP platforms—while emerging modalities like exosome therapy and 3D-printed constructs show immense translational potential. Furthermore, the integration of AI-driven treatment planning and immune-modulating hydrogels is expanding the boundaries of technical feasibility.

Nevertheless, significant barriers persist. Clinical predictability remains contingent upon defect morphology, patient-specific systemic variables, and economic constraints. The field currently necessitates standardized reporting metrics, regulatory harmonization, and rigorous long-term longitudinal data to ensure clinical consistency. Ultimately, the convergence of personalized medicine, predictive algorithms, and minimally invasive technologies heralds a new era. As these innovations transition from experimental frameworks to clinical reality, the coming decade promises to transform periodontal regeneration from a niche specialized procedure into a predictable, accessible standard of care.

References

Here is the References section, meticulously standardized and formatted into a consistent Vancouver style to match the professional tone of your article. I have corrected inconsistencies in author names (converting full names to initials) and removed metadata tags (like "JOURNAL=") for a clean, publication-ready look.

1. Trindade D, Carvalho R, Machado V, Chambrone L, Mendes JJ, Botelho J. Prevalence of periodontitis in dentate people between 2011 and 2020: A systematic review and meta-analysis of epidemiological studies. J Clin Periodontol. 2023;50(1):38–52.

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

2. Bourgeois D, Inquimbert C, Ottolenghi L, Carrouel F. Periodontal pathogens as risk factors of cardiovascular diseases, diabetes, rheumatoid arthritis, cancer, and COPD—Is there cause for consideration? Microorganisms. 2019;7(10):424.
3. Renvert S, Sanmartin Berglund J, Persson GR, Söderlin MK. The association between rheumatoid arthritis and periodontitis in a population-based case-control study. BMC Rheumatol. 2020;4:31.
4. Tonetti MS, Van Dyke TE; EFP/AAP Workshop. Periodontitis and atherosclerotic cardiovascular disease: consensus report. J Periodontol. 2019;90(Suppl 12):S24–29.
5. Athul A, Arulmari S, Muthukali S, Balachandran A, Vijayarangan A, Elumalai A. Periodontal Wound Healing- A Review. Int J Dent Res. 2022;7(3):78-82.
6. Woo HN, Cho YJ, Tarafder S, Lee CH. The recent advances in scaffolds for integrated periodontal regeneration. Bioact Mater. 2021;6(10):3328-3342.
7. Poblano-Pérez LI, Castro-Manrreza ME, González-Alva P, Fajardo-Orduña GR, Montesinos JJ. Mesenchymal Stromal Cells Derived from Dental Tissues: Immunomodulatory Properties and Clinical Potential. Int J Mol Sci. 2024;25(4):1986.
8. Lin H, Chen H, Zhao X, Chen Z, Zhang P, Tian Y, et al. Advances in mesenchymal stem cell conditioned medium-mediated periodontal tissue regeneration. J Transl Med. 2021;19(1):456.
9. Yan X, Yan F, Mohammed HAG, Liu O. Maxillofacial-Derived Mesenchymal Stem Cells: Characteristics and Progress in Tissue Regeneration. Stem Cells Int. 2021;2021:5516521.
10. Liu J, Chen B, Bao J, Zhang Y, Lei L, Yan F. Macrophage polarization in periodontal ligament stem cells enhanced periodontal regeneration. Stem Cell Res Ther. 2019;10(1):320.
11. Wei L, Yan W, Shah W, Zhang Z, Wang M, Liu B, et al. Advancements and challenges in stem cell transplantation for regenerative medicine. Heliyon. 2024;10(16):e35836.
12. Fraser D, Caton J, Benoit DSW. Periodontal Wound Healing and Regeneration: Insights for Engineering New Therapeutic Approaches. Front Dent Med. 2022;3:815810.
13. Iizumi R, Honda M. Wnt/β-Catenin Signaling Inhibits Osteogenic Differentiation in Human Periodontal Ligament Fibroblasts. Biomimetics. 2022;7(4):224.
14. Mize T, Sundararaj K, Leite R, Huang Y. Increased and correlated expression of connective tissue growth factor and transforming growth factor beta 1 in surgically removed periodontal tissues with chronic periodontitis. J Periodontal Res. 2014;50(3):315-322.

15. Raica M, Cimpean AM. Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy. Pharmaceuticals. 2010;3(3):572-599.
16. Murakami T, Matsugami D, Yoshida W, Imamura K, Bizenjima T, Seshima F, Saito A. Healing of Experimental Periodontal Defects Following Treatment with Fibroblast Growth Factor-2 and Deproteinized Bovine Bone Mineral. Biomolecules. 2021;11(6):805.
17. Chen B, Li S, Chang Y, Zhang J, Liu J, Dong Y, Yan F. Macrophages contribute to periodontal wound healing mainly in the tissue proliferation stage. J Periodontal Res. 2023;58(1):122-130.
18. Wang S, Yang Y, Li S, Chen H, Zhao Y, Mu J. Recent advances in macrophage-derived exosomes as delivery vehicles. Nano TransMed. 2022;1(2–4):e9130013.
19. Mathew R, Bhatsange A. Demineralized freeze-dried bone allograft with/without i-Platelet-rich fibrin in 3 wall intrabony defects. Braz J Oral Sci. 2024;23:e240338.
20. Kang J, Shibasaki M, Terauchi M, Oshibe N, Hyodo K, Marukawa E. Comparative analysis of the in vivo kinetic properties of various bone substitutes filled into a peri-implant canine defect model. J Periodontal Implant Sci. 2024;54(2):96-107.
21. Shaheen MY. Nanocrystalline hydroxyapatite in periodontal bone regeneration: A systematic review. Saudi Dent J. 2022;34(8):647-660.
22. Wei L, Teng F, Deng L, Liu G, Luan M, Jiang J, et al. Periodontal regeneration using bone morphogenetic protein 2 incorporated biomimetic calcium phosphate in conjunction with barrier membrane: A pre-clinical study in dogs. J Clin Periodontol. 2019;46(12):1254-1263.
23. Santos MS, Dos Santos AB, Carvalho MS. New Insights in Hydrogels for Periodontal Regeneration. J Funct Biomater. 2023;14(11):545.
24. Nikolova MP, Chavali MS. Recent advances in biomaterials for 3D scaffolds: A review. Bioact Mater. 2019;4:271-292.
25. Fan L, Wu D. Enamel Matrix Derivatives for Periodontal Regeneration: Recent Developments and Future Perspectives. J Healthc Eng. 2022;2022:8661690.
26. Lee JH, Jeong SN. Long-term stability of adjunctive use of enamel matrix protein derivative on porcine-derived xenograft for the treatment of one-wall intrabony defects: A 4-year extended follow-up of a randomized controlled trial. J Periodontol. 2022;93(2):229-236.
27. Moldovan R, Mester A, Piciu A, Bran S, Onisor F. Clinical Outcomes of Enamel Matrix Derivate Used in Surgical and Non-Surgical Treatment of Peri-Implantitis: A Systematic Review of Clinical Studies. Medicina (Kaunas). 2022;58(12):1819.

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

28. Ugale GM, Male RB, Bhandari VD, Baghele ON, Metri R, Ugale MS. Evaluation of platelet-rich fibrin in the treatment of decorticated intrabony defects: a randomized clinical trial. Quintessence Int. 2023;54(10):808-820.
29. Khan A, Ali I, Pradhan H, Shamim Khan S, Tripathi A, Ali R. Platelet-Rich Fibrin-Enhanced Bone Healing Co-grafted With Either Hydroxyapatite and Beta Tricalcium Phosphate or Demineralized Freeze-Dried Bone in Small Maxillofacial Osseous Defects: A Clinical Comparison. Cureus. 2023;15(8):e44048.
30. Valenzuela-Mencia J, Manzano-Moreno FJ. Applications of Platelet-Rich Fibrin (PRF) Membranes Alone or in Combination with Biomimetic Materials in Oral Regeneration: A Narrative Review. Biomimetics. 2025;10(3):172.
31. Nair UP, Shivamurthy R, Nagate RR, Chaturvedi S, Al-Qahtani SM, Magbol MA, et al. Effect of Injectable Platelet-Rich Fibrin with a Nano-Hydroxyapatite Bone Graft on the Treatment of a Grade II Furcation Defect. Bioengineering. 2022;9(11):602.
32. Geisinger ML. NexGen regen? Challenges and opportunities for growth factors and signaling agents in periodontal regeneration at intrabony defects. Front Dent Med. 2023;4:1239149.
33. Seo BB, Chang HI, Choi H, Koh JT, Yun KD, Lee JY, Song SC. New approach for vertical bone regeneration using in situ gelling and sustained BMP-2 releasing poly(phosphazene) hydrogel system on peri-implant site with critical defect in a canine model. J Biomed Mater Res B Appl Biomater. 2018;106(2):751-759.
34. Zhang Y, Chen X, Yang X, Huang L, Qiu X. Mesenchymal Stem Cell-Derived from Dental Tissues-Related lncRNAs: A New Regulator in Osteogenic Differentiation. J Tissue Eng Regen Med. 2023;2023:4622584.
35. Iwata T, Yamato M, Washio K, Yoshida T, Tsumanuma Y, Yamada A, et al. Periodontal regeneration with autologous periodontal ligament-derived cell sheets - A safety and efficacy study in ten patients. Regen Ther. 2018;9:38-44.
36. Wen S, Zheng X, Yin W, et al. Dental stem cell dynamics in periodontal ligament regeneration: from mechanism to application. Stem Cell Res Ther. 2024;15:389.
37. Basu A, Rothermund K, Ahmed MN, Syed-Picard FN. Self-Assembly of an Organized Cementum-Periodontal Ligament-Like Complex Using Scaffold-Free Tissue Engineering. Front Physiol. 2019;10:422.
38. Zhao Y, Gong Y, Liu X, He J, Zheng B, Liu Y. The Experimental Study of Periodontal Ligament Stem Cells Derived Exosomes with Hydrogel Accelerating Bone Regeneration on Alveolar Bone Defect. Pharmaceutics. 2022;14(10):2189.

Received: 08-06-2025 **Revised: 15-07-2025** **Accepted: 11-08-2025**

39. Murab S, Herold S, Hawk T, Snyder A, Espinal E, Whitlock P. Advances in additive manufacturing of polycaprolactone based scaffolds for bone regeneration. J Mater Chem B. 2023;11(31):7250-7279.
40. Figueiredo TM, Do Amaral GCLS, Bezerra GN, Nakao LYS, Villar CC. Three-dimensional-printed scaffolds for periodontal regeneration: A systematic review. J Indian Soc Periodontol. 2023;27(5):451-460.
41. Wang C, Li T, Zeng X, Wu L, Gao M, Tong N, et al. Sustained delivery of IL-10 by self-assembling peptide hydrogel to reprogram macrophages and promote diabetic alveolar bone defect healing. Dent Mater. 2023;39(4):418-429.
42. Santos MS, Carvalho MS, Silva JC. Recent Advances on Electrospun Nanofibers for Periodontal Regeneration. Nanomaterials (Basel). 2023;13(8):1307.
43. Meenakshi SS, Sankari M. Effectiveness of Chitosan Nanohydrogel as a Bone Regenerative Material in Intrabony Defects in Patients With Chronic Periodontitis: A Randomized Clinical Trial. J Adv Oral Res. 2021;12(2):222-228.
44. Silviya S, C.M. A, Prakash PSG, Bahammam SA, Bahammam MA, Almarghlani A, et al. The Efficacy of Low-Level Laser Therapy Combined with Single Flap Periodontal Surgery in the Management of Intrabony Periodontal Defects: A Randomized Controlled Trial. Healthcare. 2022;10(7):1301.
45. Nibali L, Koidou VP, Nieri M, Barbato L, Pagliaro U, Cairo F. Regenerative surgery versus access flap for the treatment of intra-bony periodontal defects: A systematic review and meta-analysis. J Clin Periodontol. 2020;47 Suppl 22:320-351.
46. Saka N, Kabacaoglu B, Özener HÖ. Management of intrabony defects using enamel matrix derivative. Int Dent J. 2024;74(Suppl 1):S281.
47. Rakhewar PS, et al. An evaluation of clinical effects of i-PRF as an adjunctive to non-surgical periodontal therapy versus non-surgical periodontal therapy alone in treatment of chronic periodontitis patients – a split mouth randomized controlled clinical trial. IOSR J Dent Med Sci. 2021;20(09):11-18.
48. Theodosaki AM, Filippou S, Kazantzidis G, Doufexi AE. Effectiveness of platelet rich fibrin alone or in combination with bone grafts in the treatment of infrabony defects: Systematic review and meta analysis. Health Sci Rev. 2022;5:100066.
49. Maroo S, Murthy KRV. Clinical and radiographic evaluation of rhPDGF + β TCP in an intrabony defect: a case report. J Indian Soc Periodontol. 2014;18(6):789–793.
50. Nevins M, et al. Treatment of periodontal intrabony defects using β TCP alone or with rhPDGF BB: RCT. J Periodontol. 2014;85(1):124–130.

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

51. Nevins M, et al. 36 month stability after rhPDGF BB clinical trial. [Citation details needed for full verification].
52. Chen FM, Gao LN, Tian BM, et al. Treatment of periodontal intrabony defects using autologous PDLSCs: randomized clinical trial. Stem Cell Res Ther. 2018;9(1):260.
53. de Oliveira PDS, et al. PDL MSC with xenogeneic bone substitute: 12 month pilot clinical trial. J Periodontal Res. 2020;55(3):413–422.
54. Levine RA, Saleh MHA, Dias DR, et al. Periodontal regeneration risk assessment in the treatment of intrabony defects. Clin Adv Periodontics. 2024;14:201–210.
55. Bhavsar AK, Parween S, Varadhan S, Prabhuji MLV. Critical Issues in Periodontal Regeneration - A Review. J Oral Health Dent. 2018;1(2):50-58.
56. Plonka AB, Sheridan RA, Wang HL. Flap Designs for Flap Advancement During Implant Therapy: A Systematic Review. Implant Dent. 2017;26(1):145-152.
57. Hourd P, Chandra A, Medcalf N, et al. Regulatory challenges for the manufacture and scale-out of autologous cell therapies. In: StemBook. Cambridge (MA): Harvard Stem Cell Institute; 2014.
58. Sculean A, Chiantella GC, Arweiler NB, Becker J, Schwarz F, Stavropoulos A. Five-year clinical and histologic results following treatment of human intrabony defects with an enamel matrix derivative combined with a natural bone mineral. Int J Periodontics Restorative Dent. 2008;28(2):153-61.
59. Lee JH, Jeong SN. Long-term results of regenerative treatment of intrabony defects: a cohort study with 5-year follow-up. BMC Oral Health. 2024;24(1):34.
60. De Ry SP, Roccuzzo A, Lang NP, Sculean A, Salvi GE. Long-term clinical outcomes of periodontal regeneration with enamel matrix derivative: A retrospective cohort study with a mean follow-up of 10 years. J Periodontol. 2022;93:548–559.
61. Bousnaki M, Beketova A, Kontonasaki E. A Review of In Vivo and Clinical Studies Applying Scaffolds and Cell Sheet Technology for Periodontal Ligament Regeneration. Biomolecules. 2022;12:435.
62. Rebeiz T, Lawand G, Martin W, Gonzaga L, Revilla-León M, Khalaf S, Megarbané JM. Development of an artificial intelligence model for assisting periodontal therapy decision-making: A retrospective longitudinal cohort study. J Dent. 2025;159:105780.
63. Mujawar FS, Zope SA, Suragimath G, Varma S, Kale AV. Salivary Macrophage Inflammatory Protein-1α Levels in Periodontitis Subjects Receiving Non-surgical Periodontal Therapy With and Without Photo-Biomodulation: A Prospective Interventional Controlled Trial. Cureus. 2024;16(9):e68980.

Received: 08-06-2025 Revised: 15-07-2025 Accepted: 11-08-2025

64. Li X, Zhao D, Xie J, et al. Deep learning for classifying the stages of periodontitis on dental images: a systematic review and meta-analysis. BMC Oral Health. 2023;23:1017.
65. Wang Y, Li J, Tang M, Peng C, Wang G, Wang J, et al. Smart stimuli-responsive hydrogels for drug delivery in periodontitis treatment. Biomed Pharmacother. 2023;162:114688.
66. Li C, Du Y, Zhang T, Wang H, Hou Z, Zhang Y, et al. "Genetic scissors" CRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair. Bioact Mater. 2022;22:254-273.
67. Pasqualini E, Castro F, Curado D, Martelete A, Heboyan A, Saleh MH, Fernandes JCH, Fernandes GVO. Minimally invasive periodontal regeneration with the buccal approach: a systematic review and meta-analysis of clinical studies. Evid Based Dent. 2024;25(1):54.
68. Shi J, Wang J, Yang Z, Li J, Lei L, Li H. A novel periodontal endoscopy-aided non-incisional periodontal regeneration technique in the treatment of intrabony defects: a retrospective cohort study. BMC Oral Health. 2023;23(1):962.